These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26527730)

  • 1. Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.
    Kharma N; Varin L; Abu-Baker A; Ouellet J; Najeh S; Ehdaeivand MR; Belmonte G; Ambri A; Rouleau G; Perreault J
    Nucleic Acids Res; 2016 Feb; 44(4):e39. PubMed ID: 26527730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes.
    Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting allosteric ribozymes.
    Piganeau N
    Methods Mol Biol; 2012; 848():317-28. PubMed ID: 22315077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
    Tang J; Breaker RR
    RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes.
    Citti L; Rainaldi G
    Curr Gene Ther; 2005 Feb; 5(1):11-24. PubMed ID: 15638708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computational approach to predict suitable target sites for trans-acting minimal hammerhead ribozymes.
    Mercatanti A; Lande C; Citti L
    Methods Mol Biol; 2012; 848():337-56. PubMed ID: 22315079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast.
    Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From alpaca to zebrafish: hammerhead ribozymes wherever you look.
    Seehafer C; Kalweit A; Steger G; Gräf S; Hammann C
    RNA; 2011 Jan; 17(1):21-6. PubMed ID: 21081661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An allosteric ribozyme generator and an inverse folding ribozyme generator: Two computer programs for automated computational design of oligonucleotide-sensing allosteric hammerhead ribozymes with YES Boolean logic function based on experimentally validated algorithms.
    Kaloudas D; Penchovsky R
    Comput Biol Med; 2022 Jun; 145():105469. PubMed ID: 35398809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
    Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
    Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cis-Acting 5' hammerhead ribozyme optimization for in vitro transcription of highly structured RNAs.
    Meyer M; Masquida B
    Methods Mol Biol; 2014; 1086():21-40. PubMed ID: 24136596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clone, expression and cleavage activity of anti-caspase-7 hammerhead ribozyme in vitro].
    Zhang W; Xie Q; Zhou XQ; Jiang S; Jin YX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):684-7. PubMed ID: 15623380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and application of asymmetric hammerhead ribozymes.
    Hammann C; Tabler M
    Methods; 1999 Jul; 18(3):273-80. PubMed ID: 10454985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of hammerhead ribozymes to modulate endogenous gene expression for functional studies.
    Fritz JJ; Lewin A; Hauswirth W; Agarwal A; Grant M; Shaw L
    Methods; 2002 Oct; 28(2):276-85. PubMed ID: 12413427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetracycline-regulated expression of hammerhead ribozymes in vivo.
    Bowden ET; Riegel AT
    Methods Mol Biol; 2004; 252():179-94. PubMed ID: 15017049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.